Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 16Glioma 14Neoplasms 13Breast Neoplasms 13Prostatic Neoplasms 12Brain Neoplasms 10Colorectal Neoplasms 9Neoplasm Metastasis 8Lymphoma, B-Cell 8Pancreatic Neoplasms 7Multiple Myeloma 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Recurrence 5Head and Neck Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Skin Neoplasms 4Lymphoma 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Solid Tumor 3Pituitary Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Colonic Neoplasms 3Astrocytoma 3

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pathologic Complete Response × 90 days × Clear all
NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
17 enrolled

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡